Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 9/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 9/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998454 | 0.98 | DAO (0.46) | DAOGPR35KDRGRIN3BGRIN1 | |
| SCHEMBL199636 | 0.98 | DAO (0.46) | DAOGPR35KDRGRIN3BGRIN1 | |
| SCHEMBL198179 | 0.85 | GRIN3B (0.38) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL10288661 | 0.84 | USP7 (0.42) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL2210877 | 0.84 | SIRT3 (0.46) | KDRGRIN3BGRIN1GRIN2CGRIN2D | |
| SCHEMBL1460546 | 0.83 | KDR (0.46) | KDRGRIN3BGRIN1GRIN2CGRIN2D | |
| SCHEMBL29368150 | 0.83 | KDR (0.46) | KDRGRIN3BGRIN1GRIN2CGRIN2D | |
| Lithium Ion SCHEMBL29365874 | 0.83 | GRIN3B (0.36) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| Lithium Ion SCHEMBL198644 | 0.83 | GRIN3B (0.36) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| Hydrochloric Acid SCHEMBL29368472 | 0.82 | KDR (0.45) | KDRGRIN3BGRIN1GRIN2CGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| EP-3994140-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994141-A1 | MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| CN-114008054-A | NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008053-A | Prodrugs of NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| WO-2021001423-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021001420-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | DAO 1864/4885GPR35 3321/4885KDR 1886/4885 |
| US-11466027-B2 | Modulators of the NMDA receptor | GRIN1, GRIN2A, GRIN3A | DAO 809/4885GPR35 95/4885KDR 3017/4885 |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | DAO 4577/4885GPR35 3848/4885KDR 3201/4885 |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | DAO 2880/4885GPR35 3244/4885KDR 62/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | DAO 564/4885GPR35 72/4885KDR 1861/4885 |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | DAO 564/4885GPR35 72/4885KDR 1861/4885 |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | DAO 4587/4885GPR35 3734/4885KDR 3335/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | DAO 1355/4885GPR35 2098/4885KDR 1885/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | DAO 564/4885GPR35 72/4885KDR 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.